Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
| Autor: | Kien Thiam Tan, Chiao-En Wu, Ca Tung Ng |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment Medicine (miscellaneous) Case Report olaparib Olaparib Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine.artery medicine homologous recombination repair (HRR) next-generation sequencing (NGS) comprehensive genetic profiling (CGP) Ifosfamide business.industry primary pulmonary artery sarcoma (PPAS) DNA Repair Pathway medicine.disease PARP inhibitor 030104 developmental biology chemistry 030220 oncology & carcinogenesis Pulmonary artery Cancer research Medicine Sarcoma Haploinsufficiency business medicine.drug |
| Zdroj: | Journal of Personalized Medicine Journal of Personalized Medicine, Vol 11, Iss 357, p 357 (2021) |
| ISSN: | 2075-4426 |
| DOI: | 10.3390/jpm11050357 |
| Popis: | Primary pulmonary artery sarcoma (PPAS) is a rare malignancy arising from mesenchymal pulmonary artery cells and mimics pulmonary embolism. Palliative chemotherapy such as anthracycline- or ifosfamide-based regimens and targeted therapy are the only options. However, the evidence of clinically beneficial systemic treatment is scarce. Here, we report a case of disseminated PPAS achieving clinical tumor response to olaparib based on comprehensive genetic profiling (CGP) showing genetic alterations involving DNA repair pathway. This provides supportive evidence that olaparib could be a promising therapeutic agent for patients with disseminated PPAS harboring actionable haploinsufficiency of DNA damage repair (DDR). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|